News >

Enzalutamide Succeeds in Phase III Nonmetastatic CRPC Trial

Jason M. Broderick @jasoncology
Published: Thursday, Sep 14, 2017

Dr. Mace Rothenberg

Mace Rothenberg, MD
Adding enzalutamide (Xtandi) to androgen deprivation therapy (ADT) significantly improved metastasis-free survival (MFS) versus ADT alone in patients with nonmetastatic castration-resistant prostate cancer (CRPC), according to findings from the phase III PROSPER trial.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Clinical Practice Connections™: New York Advanced Practice CollaborativeNov 15, 20191.25
Publication Bottom Border
Border Publication